Expanding human embryonic stem cells with a fixed bed reactor system

ViaCyte has been looking into alternative treatments for people with Type 1 diabetes, such as using stem-cell-derived islet replacement therapy to reduce or even do away with insulin injections entirely.

According to information provided on the company’s website, ViaCyte researchers were the first to describe the directed differentiation of human pluripotent stem cells into insulin-expressing pancreatic cells and the first to show that these cells could faithfully secrete insulin in response to elevated blood glucose in pre-clinical models.

Expanding human embryonic stem cells with a fixed bed reactor system

Image Credit: Corning Life Sciences

In both preclinical and clinical studies, ViaCyte has demonstrated that these cells differentiate in vivo from all the cell types that make up the human pancreatic islet.

According to Hannah Rasby, senior process development engineer at ViaCyte, islet cell replacement therapy faces a challenge when it comes to producing enough cells to serve the patient population that is in need of this ground-breaking treatment, despite the tremendous promise that cell therapy has shown.

Both advantages and drawbacks are present in the existing techniques of an adherent cell culture system and a 3D suspension-based system.

In addition, moving from adherent to 3D can present significant challenges and may extend development and introduce risks as engineers must adapt the process to a new form of cell culture, depending on the cell line and process. 

Scientists from ViaCyte evaluated a number of technologies using a checklist of important criteria in an effort to find a solution that might be able to address the shortcomings of these systems. This evaluation eventually led to the testing of the Corning® Ascent® FBR system.

About Corning Life Sciences

A division of Corning Incorporated, Corning Life Sciences is a leading global manufacturer of cell culture products and solutions that enable academic, biotech and biopharma scientists to harness the power of cells to create life-changing innovations. Corning supports a range of application areas including core cell culture, 3D cell culture, bioprocess, cancer research, primary and stem cell research, drug screening, cell and gene therapy, disease modeling, lab automation and more.

Whether your goal is stem cell expansion or viral vector production, Corning Life Sciences platforms, including HYPERStack® vessels that maximize cell growth area in a small footprint, the high-yield Ascent® Fixed Bed Reactor platform, microcarriers, and closed system solutions can help get you there. Choose from hundreds of vessels, the widest selection of cell culture surfaces, and custom media in a variety of single-use technology configurations. Learn more at www.corning.com/lifesciences.

Last updated: Nov 16, 2022 at 9:44 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Corning Life Sciences. (2022, November 16). Expanding human embryonic stem cells with a fixed bed reactor system. News-Medical. Retrieved on December 02, 2022 from https://www.news-medical.net/whitepaper/20221116/Expanding-human-embryonic-stem-cells-with-a-fixed-bed-reactor-system.aspx.

  • MLA

    Corning Life Sciences. "Expanding human embryonic stem cells with a fixed bed reactor system". News-Medical. 02 December 2022. <https://www.news-medical.net/whitepaper/20221116/Expanding-human-embryonic-stem-cells-with-a-fixed-bed-reactor-system.aspx>.

  • Chicago

    Corning Life Sciences. "Expanding human embryonic stem cells with a fixed bed reactor system". News-Medical. https://www.news-medical.net/whitepaper/20221116/Expanding-human-embryonic-stem-cells-with-a-fixed-bed-reactor-system.aspx. (accessed December 02, 2022).

  • Harvard

    Corning Life Sciences. 2022. Expanding human embryonic stem cells with a fixed bed reactor system. News-Medical, viewed 02 December 2022, https://www.news-medical.net/whitepaper/20221116/Expanding-human-embryonic-stem-cells-with-a-fixed-bed-reactor-system.aspx.

Other White Papers by this Supplier